Exai Bio Launches Big in Series A Financing

Exai Bio, a next-generation liquid biopsy company based on the University of California, San Francisco’s technologies for early cancer detection developed in Dr. Hani Goodarzi’s laboratory, raised $67.5 million in a financing led by leading life sciences and tech investors Section 32 and Casdin Capital, with participation from and Two Sigma Ventures.”

MORE